Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDXK | O00764 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958414 | 1.00 | PDXK (0.32) | PDXK | |
| SCHEMBL28652978 | 0.82 | CSNK2A1 (0.35) | — | |
| SCHEMBL29957742 | 0.73 | — | — | |
| SCHEMBL22301636 | 0.73 | CYP11B2 (0.35) | — | |
| SCHEMBL23926100 | 0.73 | — | — | |
| SCHEMBL30721099 | 0.73 | CYP11B2 (0.35) | — | |
| SCHEMBL29958587 | 0.72 | TDP1 (0.35) | — | |
| SCHEMBL21050694 | 0.72 | TDP1 (0.35) | — | |
| SCHEMBL29958391 | 0.71 | KMT2A (0.52) | — | |
| SCHEMBL20570729 | 0.70 | MAP3K8 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116390923-A | Heterocyclic derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| EP-4135844-A1 | FUSED TRICYCLIC KRAS INHIBITORS | Incyte Corporation (US) | 2023-02-22 | — | — | EP | disclosed |
| CN-115702025-A | Fused tricyclic KRAS inhibitors | 因赛特公司 | 2023-02-14 | — | — | CN | disclosed |
| CN-115124524-A | Tricyclic derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| WO-2022198905-A1 | TRICYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2022-09-29 | — | — | WO | disclosed |
| WO-2022037631-A1 | HETEROCYCLIC DERIVATIVE AND PREPARATION METHOD THEREFOR AND USE THEREOF | 浙江海正药业股份有限公司 | 2022-02-24 | — | — | WO | disclosed |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION | 2021-11-18 | — | — | US | disclosed |
| WO-2021211864-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2021211864-A1 | FUSED TRICYCLIC KRAS INHIBITORS | INCYTE CORPORATION (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355121-A1 | FUSED TRICYCLIC KRAS INHIBITORS | KRAS, NRAS, HRAS | PDXK 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.